New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled... | May 10, 2023
United States Sacituzumab Govitecan Sacituzumab Govitecan Hziy Raj Malik Investor Relations Corporate Communications European Society For Medical Oncology
Source: marketscreener.com